← Back to Clinical Trials
Recruiting NCT06588231

NCT06588231 Effect of Individualized Exercise in Elderly Patients With Coronary Heart Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06588231
Status Recruiting
Phase
Sponsor The First Affiliated Hospital with Nanjing Medical University
Condition Coronary Heart Disease
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2023-10-17
Primary Completion 2024-12-17

Eligibility & Interventions

Sex All sexes
Min Age 60 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Individual rehabilitation exercise trainingoptimal medical therapy :aspirin, clopidogrel, statins.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2023-10-17 with a primary completion date of 2024-12-17.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The benefits of cardiac rehabilitation have been supported by a large amount of evidence-based medicine. Cardiac rehabilitation can correct cardiovascular risk factors, reduce morbidity and mortality, and improve quality of life.

Eligibility Criteria

Inclusion Criteria: * Coronary heart disease: coronary angiography confirmed patients with coronary heart disease. * Age is 60-75 years old, and the clinical sinus rhythm is stable. * Left ventricular ejection fraction was\> 40%. * Informed consent and voluntary participation. Exclusion Criteria: * Patients with severe organic cardiac and lung diseases. * Patients with hemiplegia and other physical action disorders. * A history of mental illness. * Uncontrolled hypertension, and hemodynamic instability. * Severe nephropathy and severe peripheral artery disease. * Patients with bone and joint diseases who are not suitable for exercise. * Uncontrolled endocrine system and other diseases. * Antibiotics and anti-diarrheal medications have not been used for at least 3 months.

Contact & Investigator

Central Contact

Leilei Chen

✉ Chenlei19762002@163.com

📞 18651856055

Principal Investigator

Leilei Chen

STUDY DIRECTOR

the First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Frequently Asked Questions

Who can join the NCT06588231 clinical trial?

This trial is open to participants of all sexes, aged 60 Years or older, up to 75 Years, studying Coronary Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06588231 currently recruiting?

Yes, NCT06588231 is actively recruiting participants. Contact the research team at Chenlei19762002@163.com for enrollment information.

Where is the NCT06588231 trial being conducted?

This trial is being conducted at Nanjing, China.

Who is sponsoring the NCT06588231 clinical trial?

NCT06588231 is sponsored by The First Affiliated Hospital with Nanjing Medical University. The principal investigator is Leilei Chen at the First Affiliated Hospital of Nanjing Medical University, Nanjing, China. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology